在治疗牛皮方面最佳使用生物疗法的策略:专注于secukinumab
Anna Balato1, Martina Burlando2, Anna Campanati3
1Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
Dermatology and therapy
|September 4, 2025
概括
意大利皮肤科医生为使用抗素-17A生物药物治疗牛皮 (PsO) 制定了共识声明. 这些指导方针有助于选择患者,并确保治疗牛皮的长期有效性.
科学领域:
- 皮肤病学
- 免疫学
- 药理学
背景情况:
- 牛皮 (PsO) 是一种普遍的炎症性皮肤疾病,严重影响患者的生活质量.
- 有多种生物药物用于PsO治疗,需要临床医生和患者仔细选择.
- 抗素-17A疗法,如sequinumab,为中度至重度的牛皮提供治疗选择.
研究的目的:
- 建立意大利治疗牛皮的常规临床实践中secukinumab有效使用的共识陈述.
- 为患者选择塞库金纳治疗提供指导,以最大限度地提高长期益处.
- 概述如何保持sequinumab的有效性,并促进患者坚持使用药物.
主要方法:
- 意大利牛皮咨询委员会制定共识声明.
- 专注于三个关键主题:患者选择,长期有效性策略和患者遵守的支持.
- 在现实环境中对secukinumab的临床考虑的审查.
主要成果:
- 确定了可能受益于secukinumab的患者的选择标准,包括以前没有接种过secukinumab的患者,有敏感部位的患者和具有并发症的患者.
- 维持长期有效性的策略强调患者的支持,坚持,体重控制和根据疾病恶化量身定制的治疗.
- 患者的教育,准确的评估和个性化治疗计划对于促进治疗坚持至关重要.
结论:
- 这些共识陈述为意大利皮肤科医生在选择适合治疗sequinumab的患者方面提供了实际指导.
- 这些建议旨在优化secokinumab在实践中治疗牛皮的使用.
- 这些指导方针支持以患者为中心的牛皮治疗方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
200
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
200
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236


